Experience the forefront of medical imaging with AIxSCAN’s groundbreaking ARC60 technology. Commencing clinical trials in late 2023, AIxSCAN, Inc. has garnered early success in imaging precision and consistency. Backed by additional seed funding and esteemed partnerships, including UC San Diego Health, the company aims to revolutionize diagnostic practices for lung diseases. With plans to conduct scans on over 50 patients in the U.S. and collaborate with three more institutions, AIxSCAN, Inc. is poised for a transformative impact. Endorsements from industry experts, like Norbert Pelc, Sc.D., further underscore ARC60’s potential to redefine patient care. As the company prepares for a 510k submission to the FDA in 2024, the future of medical imaging looks promising, with AIxSCAN’s ARC60 paving the way for enhanced diagnostic accuracy and improved healthcare outcomes.
AIxSCAN, Inc. embarks on a pioneering journey in medical imaging with the initiation of clinical trials for ARC60. Launched in late 2023, ARC60 demonstrates remarkable imaging precision and consistency, heralding a new era in diagnostic capabilities. Bolstered by additional funding and strategic partnerships, including with UC San Diego Health, AIxSCAN, Inc. is poised to address critical gaps in lung disease diagnosis. As the company plans to expand its clinical footprint and pursue regulatory clearance, excitement mounts within the medical community. With endorsements from renowned experts, such as Norbert Pelc, Sc.D., ARC60 stands at the forefront of innovation, promising transformative advancements in patient care.
The endeavor received a significant boost in early September 2023 when AIxSCAN, Inc. secured additional seed funding. This financial infusion was earmarked to bolster ongoing clinical trials and engineering endeavors, further propelling the company toward its goals.
UC San Diego Health emerged as the inaugural site for the clinical trials, marking a pivotal moment in AIxSCAN, Inc.’s journey toward validation and eventual market entry. The collaboration with UC San Diego Health signifies a strategic partnership aimed at advancing medical imaging capabilities and enhancing patient care.
Throughout late 2023 and early 2024, AIxSCAN, Inc. is poised to conduct scans on more than 50 patients afflicted with lung disease across various sites in the United States. This concerted effort is part of a broader initiative to amass data from up to 1,000 lung disease patients within two years. The amassed data will serve as a cornerstone for the forthcoming 510k submission to the U.S. Food and Drug Administration (FDA) in 2024, underscoring AIxSCAN, Inc.’s commitment to regulatory compliance and rigorous validation.
Simultaneously, AIxSCAN, Inc. is on the cusp of forging partnerships with three additional institutions, pending the completion of ARC60 production cycles. These partnerships signify a strategic expansion of the company’s clinical footprint and signal a growing interest within the medical community regarding the potential of ARC60 in transforming diagnostic paradigms.
Notably, Norbert Pelc, Sc.D., Professor Emeritus of Radiology at Stanford University and a distinguished member of AIxSCAN, Inc.’s Advisory Board, has expressed profound admiration for the capabilities of the ARC60 imaging platform. Dr. Pelc remarked, “This innovative technology has the potential to revolutionize diagnostic practices across a spectrum of medical conditions. While it doesn’t entirely circumvent the limitations of traditional radiography, the preliminary results from the prototype system are exceedingly promising, suggesting a significant role for this technology in clinical settings. I firmly believe that AIxSCAN’s tomosynthesis X-ray scanner holds tremendous promise as a transformative tool for the medical community, poised to enhance patient care and potentially save lives.”
Overall, AIxSCAN’s ARC60 clinical trials mark a significant milestone in the evolution of medical imaging technology. With promising early results and strategic collaborations, including with UC San Diego Health, AIxSCAN, Inc. is positioned as a leader in advancing diagnostic precision for lung diseases. The endorsement from industry luminary Norbert Pelc, Sc.D., further underscores ARC60’s potential to revolutionize patient care. As the company moves towards regulatory clearance and commercialization, the future of medical imaging appears bright, with ARC60 poised to enhance diagnostic accuracy and improve healthcare outcomes. With its innovative approach and commitment to excellence, AIxSCAN, Inc. sets a new standard for medical imaging, shaping the landscape of healthcare delivery for years to come.
